Baseline characteristics of the NASA registry versus the SWIFT and TREVO 2 trials
| Characteristic | NASA registry (n=354) | SWIFT trial (n=58) | p Value NASA vs SWIFT | TREVO 2 trial (n=88) | p Value NASA vs TREVO 2 |
|---|---|---|---|---|---|
| Age (years) (mean (SD)) | 67.3 (15.2) | 67.1 (12.0) | 0.9 | 67.4 (13.9) | 0.9 |
| Sex (% male) | 178 (50.4) | 52 | 0.9 | 55 | 0.5 |
| Atrial fibrillation (n (%) or %) | 148 (42) | 45 | 0.7 | 48 | 0.4 |
| Diabetes mellitus (n (%) or %) | 87 (25) | 24 | 0.9 | 38 | 0.05 |
| Hypertension (n (%) or %) | 271 (77) | 72 | 0.4 | 76 | 0.8 |
| Hyperlipidemia (n (%) or %) | 182 (52) | 53 | 0.9 | 63 | 0.1 |
| Smoking history (n (%) or %) | 108 (31) | 40 | 0.2 | 42 | 0.11 |
| Coronary artery disease (n (%) or %) | 111 (32) | 33 | 0.9 | 33 | 0.9 |
| NIHSS score (mean (SD)) | 18.1 (6.6) | 17.3 (4.5) | 0.3 | 18.3 (5.3) | 0.6 |
| MCA/M1 (n (%) or %) | 197 (56) | 66 | 0.2 | 60 | 0.6 |
| ICA terminus (n (%) or %) | 82 (23.2) | 21 | 0.7 | 16 | 0.2 |
| Basilar (n (%) or %) | 36 (10.2) | 2 | 0.05 | 8 | 0.6 |
| Time of onset to groin puncture (min/h) (mean (SD)) | 363.4 (239)/6.1 (4) | 301.6 (71.2)/5 (1.2) | <0.001 | 276 (90)/4.5 (1.5) | <0.001 |
| Time to revascularization or end of procedure (min) (median (IQR)/mean (SD)) | 50 (30.8–78.8)/77 (96.3) | 36 (18–65)/NA | NA/47.8 (44.2) | <0.001 |
Significant differences are indicated in bold type.
ICA, internal carotid artery; MCA, middle cerebral artery; NASA, North American Solitaire Acute Stroke registry; NIHSS, National Institute of Health Stroke Scale; SWIFT trial, Solitaire with the Intention for Thrombectomy trial; TREVO 2 trial, Trevo versus Merci retrievers for thrombectomy revascularization of large vessel occlusions in acute ischemic stroke trial.